Latest News & Features
Americas
LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18. 11 June 2015
Americas
Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more. 11 June 2015
Big Pharma
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal. 11 June 2015
Asia-Pacific
The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17. 11 June 2015
Asia
Police in the Philippines have raided a call centre in Manila whose operators had allegedly been selling counterfeit drugs, including copies of Pfizer’s Viagra (sildenafil), over the phone. 10 June 2015
Americas
The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda. 10 June 2015
Big Pharma
Pfizer has apologised to UK-based healthcare providers for any confusion or increased workload following the English High Court’s decision on a patent infringement case centring on its epilepsy drug Lyrica. 9 June 2015
Americas
Hedge fund manager Kyle Bass has filed another petition for an inter partes review of a patent covering Horizon Pharma’s arthritis drug Vimovo. 9 June 2015
Big Pharma
The English High Court has ordered Novartis to pay 75% of the defendants’ legal costs in a patent infringement case against Focus Pharmaceuticals, Actavis and Teva. 8 June 2015
Americas
The US Court of Appeals for the Federal Circuit has heard oral arguments in Amgen v Sandoz, a case that should determine whether it is mandatory for biosimilar applicants to engage in the so-called patent dance. 8 June 2015